Frontiers in Immunology, 2021 Granzyme B is a renowned effector molecule primarily utilized by CTLs and NK cells against ill-defined and/or transformed cells during immunosurveillance.
Jishuang Liu, Ye Qiu, Qiu Zhidong
exaly +3 more sources
Changes in Cell-Mediated Immunity (IFN-γ and Granzyme B) Following Influenza Vaccination
Viruses, 2021 Interferon gamma (IFN-γ) is considered a key moderator of cell-mediated immunity. However, little is known about its association with granzyme B, which plays an important role in the effector function of cytotoxic T lymphocytes (CTLs).
Naruhito Otani +2 more
exaly +3 more sources
Modulation of Inflammation by Extracellular Granzyme A [PDF]
Frontiers in Immunology, 2020 Granzyme A (GrA) has long been recognized as one of the key players in the induction of cell death of neoplastic, foreign or infected cells after granule delivery by cytotoxic cells.
Kim R. van Daalen +3 more
doaj +4 more sources
Granzyme B PET Imaging of the Innate Immune Response
Molecules, 2020 The human immune system is a complex system which protects against invaders and maintains tissue homeostasis. It is broadly divided into the innate and adaptive branches. Granzyme B is serine protease that plays an important role in both and can serve as
Mikhail Doubrovin +2 more
exaly +3 more sources
Aberrant intra‐epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103‐β7‐receptor‐mediated granzyme‐B degranulation which can be restored by etrolizumab [PDF]
Clinical & Translational ImmunologyObjectives Refractory celiac disease type II (RCDII) is an intestinal tumor of aberrant intra‐epithelial T‐lymphocytes (IEL). The severe enteropathy found in RCDII is caused by aberrant IEL that exert cytotoxicity against enterocytes.
Daan A R Castelijn +18 more
doaj +2 more sources
Development of a novel 18F-labeled radiotracer targeting granzyme B for imaging early tumor responses to immunotherapy [PDF]
Journal for ImmunoTherapy of CancerBackground Immunotherapy has emerged as a promising avenue for malignant tumors treatment, but methods to validate its in vivo antitumor activity remain limited.
Xiao Wang +4 more
doaj +2 more sources
Decreased Expression of Cytotoxic Proteins in Decidual CD8+ T Cells in Preeclampsia
Biology, 2021 In our study, we aimed to establish expression of cytotoxic CD8+ T cells in the decidua basalis and the maternal peripheral blood (mPBL) of severe and mild preeclampsia (PE) and compare to healthy pregnancies.
Violeta Soljic +8 more
doaj +1 more source
Improved Purification of Human Granzyme A/B and Granulysin Using a Mammalian Expression System
Frontiers in Immunology, 2022 Cytotoxic lymphocytes release proteins contained within the cytoplasmic cytolytic granules after recognition of infected or tumor target cells. These cytotoxic granular proteins (namely granzymes, granulysin, and perforin) are key immunological mediators
Valerio Rasi +10 more
doaj +1 more source
Journal of Cell Science, 2006 Defence against virally infected and malignant cells depends on the action of cytotoxic T lymphocytes and natural killer cells ([Barry and Bleackley, 2002][1]; [Russell and Ley, 2002][2]). Although these use several mechanisms to eliminate target cells, the principal event is secretion of ...
Bots, Michael, Medema, Jan Paul
openaire +3 more sources
Granzyme B is dispensable in the development of diabetes in non-obese diabetic mice. [PDF]
PLoS ONE, 2012 Pancreatic beta cell destruction in type 1 diabetes is mediated by cytotoxic CD8(+) T lymphoctyes (CTL). Granzyme B is an effector molecule used by CTL to kill target cells.
Zia U Mollah +7 more
doaj +1 more source